Anticoagulant News and Research

RSS

New UTMB study finds no association between testosterone therapy and blood clots in veins

A new study from The University of Texas Medical Branch at Galveston of more than 30,000 commercially insured men is the first large comparative analysis to show that there is no link between testosterone therapy and blood clots in veins. The study found that middle-aged and older men who receive testosterone therapy are not at increased risk of this illness.

21 Jul 2015

Alternative approach to treat fatal blood clots found to be more effective in patients

Potentially fatal blood clots account for thousands of emergency room visits each year and often those patients are admitted to the hospital, treated with an injectable anticoagulant and monitored for a few days.

17 Jul 2015

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

The National Institute for Health and Care Excellence has recommended a new treatment to help patients suffering from blood clots in the legs and lungs.

13 Jul 2015

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Today AbbVie announced the European Commission granted marketing authorization for IMBRUVICA (ibrutinib) as the first treatment option available in all 28 member states of the European Union for the treatment of Waldenstrom's macroglobulinemia (WM), a rare, slow growing blood cancer, in adult patients who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.

12 Jul 2015

Mild head injury patients having lower serum S100B levels unlikely to have intracranial hemorrhage

Researchers conducted a prospective observational study in elderly patients and adult patients receiving antiplatelet therapy who presented with mild head injury at two trauma hospitals in Vienna: the Trauma Hospital Meidling and the Donauspital.

7 Jul 2015

DGIST researchers set on creating microrobot-assisted procedure for dealing with blocked arteries

Swarms of microscopic, magnetic, robotic beads could be scrubbing in next to the world's top vascular surgeons--all taking aim at blocked arteries.

2 Jul 2015

Uninterrupted NOAC treatment during catheter ablation of atrial fibrillation is safe, shows research

Uninterrupted treatment with novel oral anticoagulants (NOACs) during catheter ablation of atrial fibrillation (AF) is safe, reveals research presented today at EHRA EUROPACE - CARDIOSTIM 2015 by Dr Carsten Wunderlich, senior consultant in the Department of Invasive Electrophysiology, Heart Centre Dresden, Germany.

25 Jun 2015

First ESC recommendations for patients with cardiac arrhythmias, CKD published in EP Europace

The first ESC recommendations for patients with cardiac arrhythmias and chronic kidney disease (CKD) are presented today at EHRA EUROPACE - CARDIOSTIM 2015 and published in EP Europace.

24 Jun 2015

Heparin market in Europe estimated to reach USD 3,148.0 million by 2022

According to a new market report published by Transparency Market Research Heparin Market - Europe Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2022" the Heparin Market Europe was valued at USD 2,004.5 million in 2013 and is estimated to reach USD 3,148.0 million by 2022 growing with a CAGR of 5.2% from 2014 to 2022.

17 Jun 2015

Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

Allergan plc, a leading global pharmaceutical company, and KYTHERA Biopharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market, today announced that they have entered into a definitive agreement under which Allergan has agreed to acquire KYTHERA in a cash and equity transaction valued at $75 per KYTHERA share, or approximately $2.1 billion.

17 Jun 2015

Phase I study: Idarucizumab reverses anticoagulant effect of dabigatran in healthy volunteers

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that The Lancet published results from a phase I study investigating the effects of idarucizumab, an investigational agent, in reversing the anticoagulant effect of dabigatran in healthy volunteers. The data demonstrate that complete reversal was achieved following administration of idarucizumab.

17 Jun 2015

Study examines mental health prognosis of young VTE patients

EuroHeartCare is the official annual meeting of the Council on Cardiovascular Nursing and Allied Professions of the European Society of Cardiology. The 2015 meeting is held 14 to 15 June in Dubrovnik, Croatia, in collaboration with the Croatian Association of Cardiology Nurses.

15 Jun 2015

Expert report highlights urgent action needed to lessen the future impact of Atrial Fibrillation in Europe

Researched and written by RAND Europe, with contributions from a panel of leading European medical, patient group and health economic experts, the Future of Anticoagulation Report explores how decisions made today can change and reshape the landscape of tomorrow...

3 Jun 2015

Researchers develop hybrid tissue-engineered heart valve using patient's own cells

Researchers have created a new heart valve that combines a patient's own cells with metal alloy for a more durable replacement with potentially fewer complications, according to an article in the June 2015 issue of The Annals of Thoracic Surgery.

2 Jun 2015

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.

1 Jun 2015

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics LLC today announced interim results from the ongoing Phase Ib/II PCYC-1129 study suggesting that ibrutinib (IMBRUVICA) may be a safe and effective treatment for patients with chronic graft-versus-host-disease (cGVHD) who were either refractory to steroid treatment or were steroid-dependent.

1 Jun 2015

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or death compared to patients receiving placebo in combination with BR.

1 Jun 2015

Study suggests race-specific equations to aid clinicians better calculate warfarin dosage

A new report demonstrates that clinical and genetic factors affecting dose requirements for warfarin vary by race. The study, published online today in Blood, the Journal of the American Society of Hematology, proposes race-specific equations to help clinicians better calculate warfarin dosage.

30 May 2015

Newer anticoagulant medication may increase risk of GI bleeding in older patients

In a study released online in April in the BMJ, a team of researchers from Mayo Clinic, and other collaborators, showed that for older patients, particularly individuals greater than 75 years of age, the risk of gastrointestinal (GI) bleeding is 3 to 5 times higher when taking newer anticoagulant medications dabigatran or rivaroxaban compared to when using warfarin.

30 May 2015

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types.

28 May 2015

Anticoagulant News and Research

New UTMB study finds no association between testosterone therapy and blood clots in veins

Alternative approach to treat fatal blood clots found to be more effective in patients

Lixiana (edoxaban) recommended for treating, preventing recurrent DVT and PE in adults

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Mild head injury patients having lower serum S100B levels unlikely to have intracranial hemorrhage

DGIST researchers set on creating microrobot-assisted procedure for dealing with blocked arteries

Uninterrupted NOAC treatment during catheter ablation of atrial fibrillation is safe, shows research

First ESC recommendations for patients with cardiac arrhythmias, CKD published in EP Europace

Heparin market in Europe estimated to reach USD 3,148.0 million by 2022

Allergan agrees to acquire KYTHERA Biopharmaceuticals for $2.1 billion

Phase I study: Idarucizumab reverses anticoagulant effect of dabigatran in healthy volunteers

Study examines mental health prognosis of young VTE patients

Expert report highlights urgent action needed to lessen the future impact of Atrial Fibrillation in Europe

Researchers develop hybrid tissue-engineered heart valve using patient's own cells

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Study suggests race-specific equations to aid clinicians better calculate warfarin dosage

Newer anticoagulant medication may increase risk of GI bleeding in older patients

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News